Send a Tweet
Most Popular Choices
Share on Facebook 1 Share on Twitter Printer Friendly Page More Sharing
OpEdNews Op Eds   

TB Alliance advances next-generation TB drug candidate into clinical testing

By       (Page 2 of 2 pages) Become a premium member to see this article and all articles as one long page.     (# of views)   No comments
Author 91838
Follow Me on Twitter     Message Citizen News Service - CNS
Become a Fan
  (1 fan)
- Advertisement -

Industry cuts have been especially harmful to TB-drug development, with major companies no longer filling the pipeline with new TB leads. "With drug resistance on the rise, this is particularly worrying. New medicines can take a decade or more to develop. Without a strong backfill of fresh leads, there are worrying consequences for TB control in the future," commented Dr Mary Moran of Policy Cures.

Indeed, the TB world had to wait for 45 years between the introduction of rifampicin (in 1967) and the approval of the next new class drug bedaquiline (in 2012). Over 120 years elapsed between the advent of smear microscopy and the introduction of GeneXpert for the diagnosis of TB. And we are still waiting for a vaccine that can replace/improve the BCG vaccine introduced in 1921.

- Advertisement -

According to Dr Murray, "As TB was brought under adequate control in most of the developed world, innovation in tools to diagnose, treat, and prevent TB stalled. However, TB continued to be a leading killer in poorer regions. As AIDS emerged, TB exploded and received renewed attention as a global health threat. This led to resurgence in TB drug development, including the launch of TB Alliance in 2000. In the last few years, we have seen the introduction of two new drugs -- Sirturo (bedaquiline) and Deltyba (delamanid). However, these drugs have only been approved for use against MDR-TB and we are yet to see their major impact on the disease. What is needed is therapy that can transform TB treatment, making it short, simple, effective, and affordable for all.

- Advertisement -

New regimens in development, such as PaMZ, are believed to be able to usher in a new age of TB treatment and have major impact on the TB pandemic. TBA-354 was identified in collaboration with partners -- University of Auckland and University of Illinois Chicago. Once identified, TB Alliance further advanced TBA-354 through pre-clinical development and is now the sponsor of this Phase 1 study.

Shobha Shukla, CNS

(The author is the Managing Editor of CNS. Twitter: @shobha1shukla, @cns_health, Email: shobha|AT|citizen-news.orgEmail address, website: www.citizen-news.org)

- Shared under Creative Commons (CC) Attribution License

- Advertisement -

Next Page  1  |  2

 

- Advertisement -

Rate It | View Ratings

Citizen News Service - CNS Social Media Pages: Facebook page url on login Profile not filled in       Twitter page url on login Profile not filled in       Linkedin page url on login Profile not filled in       Instagram page url on login Profile not filled in

Citizen News Service (CNS) specializes in in-depth and rights-based, health and science journalism. For more information, please contact: www.citizen-news.org or @cns_health or www.facebook.com/cns.page
Go To Commenting
The views expressed herein are the sole responsibility of the author and do not necessarily reflect those of this website or its editors.
Writers Guidelines
Contact AuthorContact Author Contact EditorContact Editor Author PageView Authors' Articles
Support OpEdNews

OpEdNews depends upon can't survive without your help.

If you value this article and the work of OpEdNews, please either Donate or Purchase a premium membership.

STAY IN THE KNOW
If you've enjoyed this, sign up for our daily or weekly newsletter to get lots of great progressive content.
Daily Weekly     OpEdNews Newsletter
Name
Email
   (Opens new browser window)
 

Most Popular Articles by this Author:     (View All Most Popular Articles by this Author)

Management of respiratory diseases beyond drugs: Pulmonary Rehabilitation

Oxygen therapy is like a prescription drug: Use it rationally

New funding boosts research for controlling TB, malaria, dengue and leishmaniasis

Progress made but work remains on firewalling health policy from tobacco industry

World Health Day: No substitute to healthy mind

Nepal leading tobacco control in South Asia: Will it spiral domino effect on other nations?